Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.

Thomas E.  Hutson

Employment - Texas Oncology

Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer

Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer

Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer

Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)

Toni K.  Choueiri

Employment - Dana Farber Cancer Hospital

Leadership - ASCO; Dana Farber Cancer Hospital; KidneyCan; NCCN

Stock and Other Ownership Interests  - Pionyr; Tempest Therapeutics

Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; IQvia; Janssen Oncology; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)

Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response

Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel

Robert J.  Motzer

Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer

Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb

Sun Young  Rha

Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; Ipsen; MSD Oncology

Speakers' Bureau - Eisai; Eisai; Lilly

Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen

Anna  Alyasova

Honoraria - Eisai

Research Funding - Eisai

Jaime R.  Merchan

Consulting or Advisory Role - Exelixis

Research Funding - Corvus Pharmaceuticals (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Replimune (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Vyriad (Inst)

Howard  Gurney

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche

Speakers' Bureau - Merck Serono

Travel, Accommodations, Expenses - AstraZeneca

Avivit  Peer

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; MSD; Pfizer; Roche

Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Pfizer

Toshio  Takagi

No Relationships to Disclose

Camillo  Porta

No Relationships to Disclose

Thomas  Powles

Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen

Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen

Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche

Viktor  Grünwald

Stock and Other Ownership Interests  - AstraZeneca; Bristol-Myers Squibb; MSD

Honoraria - Asklepios Kliniken; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinic of Oldenburg; Diakonie Clinic; Dortmund Hospital; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche

Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Ipsen; Janssen-Cilag; Lilly; MSD Oncology; Novartis; Onkowissen; Pfizer

Research Funding - Novartis (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Pfizer

Ugo  De Giorgi

Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; Novartis; Pfizer; PharmaMar; Sanofi

Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Roche

Ulka N.  Vaishampayan

Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer

Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi

Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer

Manuela  Schmidinger

Honoraria - ALKERMES; BMS; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; MSD Oncology; Pfizer; Roche/Genentech

Consulting or Advisory Role - BMS; Eisai; EUSA Pharma; Ipsen; MSD Oncology; Pfizer; Roche

Travel, Accommodations, Expenses - BMS; Ipsen; Roche

Hilary  Glen

Consulting or Advisory Role - Astellas Pharma; Eisai; Ferring; Janssen

Travel, Accommodations, Expenses - Janssen

Karla  Rodriguez-Lopez

Employment - Merck

Leadership - Merck

Stock and Other Ownership Interests  - Merck

Honoraria - Merck

Research Funding - Merck

Travel, Accommodations, Expenses - Merck

Dongyuan  Xing

Employment - Eisai

Lea  Dutta

Employment - Eisai

Masatoshi  Eto

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Johnson & Johnson; Merck; Ono Pharmaceutical; Pfizer; Takeda

Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology; Merck; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Takeda

Research Funding - Astellas Pharma (Inst); Bayer (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)